Status:
COMPLETED
Registry for the Atopic Dermatitis Research Network
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Atopic Dermatitis Research Network
Conditions:
Atopic Dermatitis
Eczema Herpeticum
Eligibility:
All Genders
8-80 years
Brief Summary
The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant datab...
Detailed Description
People with atopic dermatitis (AD), also known as eczema, experience hot, dry, scaly skin with severe itching. In addition, people with AD are prone to skin infections and inflammation. Little is know...
Eligibility Criteria
Inclusion
- Participants who meet all of the following criteria are eligible for enrollment. Participants may be reassessed if not initially eligible.
- ADEH+ and Non-atopic males and females ages 8 months to 80 years, inclusive, at the time of Enrollment, and ADEH- males and females ages 3 years to 80 years, inclusive, at the time of Enrollment.
- Who are willing to sign the informed consent form or whose parent or legal guardian is willing to sign the informed consent form (age appropriate) prior to initiation of any study procedures.
- Who are willing to sign the assent form, if age appropriate.
- Who meet criteria for one of the diagnostic groups (ADEH-Staph+, ADEH-Staph-, ADEH+, ADEV+, Non-atopic) as defined in the ADRN Standard Diagnostic Criteria and the Staphylococcus aureus Colonization Criteria.
Exclusion
- Participants who meet any of the following criteria are not eligible for enrollment.
- Who have an active systemic malignancy; uncomplicated non-melanoma skin cancer and melanoma in situ with documentation of complete excision are not exclusionary.
- Who have any skin disease other than AD that might compromise the stratum corneum barrier (e.g., bullous diseases, psoriasis, cutaneous T cell lymphoma \[also called Mycosis Fungoides or Sezary syndrome\], dermatitis herpetiformis, Hailey-Hailey, or Darier's disease).
- Who have a history of systemic immunological illness (e.g., immunodeficiency disorders such as human immunodeficiency virus \[HIV\] or lupus erythematosus) other than the condition being studied.
- Who have a first degree relative already enrolled in the study.
- Who are determined not to be eligible in the opinion of the Investigator.
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 7 2018
Estimated Enrollment :
3387 Patients enrolled
Trial Details
Trial ID
NCT01494142
Start Date
August 1 2011
End Date
February 7 2018
Last Update
September 19 2018
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
2
National Jewish Health
Denver, Colorado, United States, 80206
3
Northwestern University
Chicago, Illinois, United States, 60611
4
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60614